Hims & Hers Health, Inc. (commonly known as Hims & Hers or HIMS) is a U.S.-based direct-to-consumer telehealth and consumer health company. It connects patients with licensed healthcare providers via a digital platform and offers prescription and over-the-counter treatments, with fulfillment through a network of partner pharmacies and home delivery. The company markets products under the Hims and Hers brands.
Its offerings span dermatology and skincare, hair loss and hair care, sexual health, and mental health, providing medications and related personal care products alongside virtual consultations and prescription management. Hims & Hers is publicly listed on the New York Stock Exchange under the ticker HIMS.
Also known as HIMS.
None yet. When a new project in the record names Hims & Hers as owner, partner or investor, it shows here.
Hims & Hers will offer FDA-approved semaglutide medicines at self-pay prices, shifting focus from compounded GLP-1 offerings to increase patient access.
Novo Nordisk seeks to stop Hims from selling unapproved semaglutide, citing patient safety risks and patent infringement.
